

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

July 09, 2018

To,  
The Manager,  
Listing Department,  
BSE Limited,  
Bombay Stock Exchange,  
P.J. Towers, Dalal Street,  
Mumbai - 400 001

**Subject:** Statement of Investor Complaints for the quarter ended 30<sup>th</sup> June 2018.


**Ref:** Scrip code 956084 and ISIN INE988W07019

Dear Sir/Madam,

With reference to the subject matter, please find below the statement on the investor complaints for Genlink Pharma Solutions Private Limited (formerly known as Genlink Pharma Investments Private Limited) as required under Regulation 13(3) of Chapter III of SEBI (Listing Obligations and Disclosure Requirements), 2015 for the quarter ended 30<sup>th</sup> June, 2018.

Particulars	Status of complaints
Investor complaints pending at the beginning of the quarter	Nil
Investor complaints received during the quarter	Nil
Investor complaints disposed of during the quarter	Not applicable
Investor complaints remaining unresolved at the end of the quarter	Nil

For Genlink Pharma Solutions Private Limited



Anand Pratulchandra Shah  
Director & Compliance Officer  
DIN: 00597145

Address: A-1801, Emerald Bay, Sector 14, Palm Beach Road,  
Nerul, Navi Mumbai, Nerul Node 3  
Thane 400706.

